Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pan-cancer antagonistic inhibition pattern of ATM-driven G2/M checkpoint pathway vs other DNA repair pathways.
Zolotovskaia MA, Modestov AA, Suntsova MV, Rachkova AA, Koroleva EV, Poddubskaya EV, Sekacheva MI, Tkachev VS, Garazha AV, Glusker AA, Seryakov AP, Vladimirova US, Rumiantsev PO, Moisseev AA, Zharkov DO, Kuzmin DV, Zhao X, Prassolov VS, Shegay PV, Li X, Steinbichler TB, Kim E, Sorokin MI, Wang Y, Buzdin AA. Zolotovskaia MA, et al. Among authors: poddubskaya ev. DNA Repair (Amst). 2023 Mar;123:103448. doi: 10.1016/j.dnarep.2023.103448. Epub 2023 Jan 13. DNA Repair (Amst). 2023. PMID: 36657260
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Brahmer J, et al. N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31. N Engl J Med. 2015. PMID: 26028407 Free PMC article. Clinical Trial.
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE. Horn L, et al. J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12. J Clin Oncol. 2017. PMID: 29023213 Free PMC article. Clinical Trial.
Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation.
Sorokin M, Kholodenko R, Grekhova A, Suntsova M, Pustovalova M, Vorobyeva N, Kholodenko I, Malakhova G, Garazha A, Nedoluzhko A, Vasilov R, Poddubskaya E, Kovalchuk O, Adamyan L, Prassolov V, Allina D, Kuzmin D, Ignatev K, Osipov A, Buzdin A. Sorokin M, et al. Oncotarget. 2017 Dec 27;9(4):5111-5124. doi: 10.18632/oncotarget.23700. eCollection 2018 Jan 12. Oncotarget. 2017. PMID: 29435166 Free PMC article.
Genome-wide methylotyping resolves breast cancer epigenetic heterogeneity and suggests novel therapeutic perspectives.
Tanas AS, Sigin VO, Kalinkin AI, Litviakov NV, Slonimskaya EM, Ibragimova MK, Ignatova EO, Simonova OA, Kuznetsova EB, Kekeeva TV, Larin SS, Poddubskaya EV, Trotsenko ID, Rudenko VV, Karandasheva KO, Petrova KD, Tsyganov MM, Deryusheva IV, Kazantseva PV, Doroshenko AV, Tarabanovskaya NA, Chesnokova GG, Sekacheva MI, Nemtsova MV, Izhevskaya VL, Kutsev SI, Zaletaev DV, Strelnikov VV. Tanas AS, et al. Among authors: poddubskaya ev. Epigenomics. 2019 May;11(6):605-617. doi: 10.2217/epi-2018-0213. Epub 2019 Feb 7. Epigenomics. 2019. PMID: 30729807 Free article.
32 results